It’s about time: mitigating cancer-related cognitive impairments through findings from computational models of the Wisconsin Card Sorting Task
AT-0174, a novel dual IDO1/TDO2 enzyme inhibitor, synergises with temozolomide to improve survival in an orthotopic mouse model of glioblastoma
Latest collections open to submissions
Cancer-associated fibroblasts
Guest edited by Lukas Lacina and Karel Smetana
Cancer vaccines
Guest edited by Leonardo O. Reis and Chunlin Ou
Quality of life and supportive care in cancer
Guest edited by Eileen Shinn and Christina Signorelli
Editors' Picks
Trending BMC Cancer Articles
Click here to view which Articles have been shared most in the last month!
Articles
-
-
Weekly carboplatin plus paclitaxel chemotherapy in advanced melanoma patients resistant to anti-PD-1 inhibitors: a retrospective, monocentric experience
-
Immunomodulatory role of tumor microenvironment on oncological outcomes in advanced laryngeal cancer
-
Bi-weekly irinotecan is an effective and convenient regimen in the treatment of relapsed or refractory small cell lung cancer
-
Prevalence, classifications and factors associated with sexual dysfunction among adult cancer patients on chemotherapy at the Uganda Cancer Institute, Mbarara
-
M1 and M2 macrophages derived from THP-1 cells differentially modulate the response of cancer cells to etoposide
-
Efficacy and safety of anti-PD-1 inhibitor versus anti-PD-L1 inhibitor in first-line treatment of extensive-stage small cell lung cancer: a multicenter retrospective study
-
An electronic application for rapidly calculating Charlson comorbidity score
-
Does colon cancer ever metastasize to bone first? a temporal analysis of colorectal cancer progression
-
Depression and anxiety among people living with and beyond cancer: a growing clinical and research priority
Targeted Therapies for Cancer
Guest edited by Prof. Min Li and Dr. Yanis Boumber
Open for submissions
Microbiome and Cancer
Guest edited by Christopher Staley, Jacques Ravel, Sean Devlin
Open for submissions
Cross journal collection: Advances in CAR-T immunotherapy
Guest edited by Profs Marko Radic, Djordje Atanackovic and Tim Luetkens
Collection published: 30 June 2020
Cross journal collection: Precision Oncology
Collection published: 28 August 2019
Browse all BMC Cancer collection contributions
MULISARC trial: molecular profiling of advanced soft-tissue sarcomas
THUNDER 2: THeragnostic Utilities for Neoplastic DisEases of the Rectum by MRI guided radiotherapy
Learn more about study protocols at BMC Cancer here
Aims and Scope
BMC Cancer is an open access, peer-reviewed journal that considers articles on all aspects of cancer research, including the pathophysiology, prevention, diagnosis and treatment of cancers. The journal welcomes submissions in broad areas of cancer research including molecular and cellular biology, genetics, epidemiology, and clinical trials. Learn more about our scope here.
Become an Editorial Board Member
We are recruiting new Editorial Board Members.
Read MoreBMC Cancer is celebrating its 20th anniversary!
Since launching in 2001, we've become established as the largest open access oncology journal in our field. We're proud of our history of making cancer research and methods available to all. We have been looking back at our achievements and highlighted some of the most influential research published in the journal over the past two decades.
BMC Series Blog
-
The BMC Blog Network has moved to the Research Communities
02 September 2024
-
-
Latest Tweets
View Twitter timeline
Your browser needs to have JavaScript enabled to view this timeline
Annual Journal Metrics
-
Citation Impact 2023
Journal Impact Factor: 3.4
5-year Journal Impact Factor: 3.8
Source Normalized Impact per Paper (SNIP): 0.944
SCImago Journal Rank (SJR): 1.087
Speed 2023
Submission to first editorial decision (median days): 12
Submission to acceptance (median days): 150
Usage 2023
Downloads: 7,974,312
Altmetric mentions: 3,975
Peer-review Terminology
-
The following summary describes the peer review process for this journal:
Identity transparency: Single anonymized
Reviewer interacts with: Editor
Review information published: Review reports. Reviewer Identities reviewer opt in. Author/reviewer communication